Rachel Salzman

WORK HISTORY

EDUCATION

SKILLS

ABOUT RACHEL SALZMAN

Dr. Rachel Salzman serves as Chief Executive Officer (CEO) at Armatus Bio, a privately held preclinical stage biotech focusing on curative approaches for neuromuscular disorders where toxic gain of function plays a causative role in disease pathology. Prior to joining Armatus, Rachel was Executive Vice President of Portfolio, External Affairs & Development at Alcyone Therapeutics, a precision medicines company advancing therapies in serious neurological disorders by integrating novel delivery technologies with innovative genetic platforms.Rachel co-founded SwanBio Therapeutics in 2017, and served as Chief Executive Officer (CEO) and Director through 2019. She was the company\'s President and Chief Portfolio & Development Officer until January 2021. She then founded UltraSquared Bio, a not-for-profit organization dedicated to bringing gene therapies to ultra-rare populations where traditional business cases are not tractable, and in this capacity was awarded a prestigious Termeer Foundation Fellowship.Prior to her time at Swan, she was the Chief Science Officer (CSO) of The Stop ALD Foundation since 2001. The Stop ALD Foundation is a non-profit Medical Research Organization dedicated to employing entrepreneurial approaches and innovative methodology towards effective therapies, cures, and prevention of X-linked adrenoleukodystrophy (ALD), an often-fatal neurodegenerative disease. As CSO she made critical contributions in driving forward the world’s first ex vivo lentiviral gene therapy clinical trial conducted in non-HIV infected patients. For over 20 years Dr. Salzman has provided drug development expertise and advice in the rare disease space where complex biological and business issues intersect with serious unmet medical need. Dr. Salzman’s impact is a result of her unique leadership ability and successful aggregation of resources and commitment from investigators, technologists, and investors. Dr. Salzman has been an active member of ASGCT (American Society of Gene and Cell Therapy) for over 20 years and has served in a leadership capacity including elected membership to the Board of Directors, along with multiple committees and task forces designed to build and enhance the state of gene and cell therapy in both the US and EU. Her many contributions were formally recognized by being designated the Sonia Skarlatos Public Service Award recipient in 2015. She currently represents ASGCT at the National Academy of Sciences Forum on Regenerative Medicine.